Stifel Reiterates Bullish View on Celgene (CELG) Amid Favorable Otezla Trends
Tweet Send to a Friend
Stifel analyst Katherine Breedis reiterated a Buy rating and $138 price target on Celgene (NASDAQ: CELG) noting favorable trends Otezla ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
